Amyris To Host First Quarter 2020 Financial Results Conference Call On May 8

On May 4, 2020 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biology solutions provider, owner of Clean Beauty consumer brands and provider of proprietary functional ingredients, reported that the company will host a conference call for investors and analysts on Friday, May 8, 2020 at 6:00 a.m. PT (9:00 a.m. ET) to discuss its first quarter 2020 results (Press release, Amyris Biotechnologies, MAY 4, 2020, View Source [SID1234556979]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release detailing first quarter 2020 results will be issued on the morning of May 8 prior to the call.

On the call, President and Chief Executive Officer John Melo, Chief Financial Officer Han Kieftenbeld, and Chief Operating Officer Eduardo Alvarez will discuss Amyris’ financial results, as well as the company’s business outlook and strategy.

Those who wish to listen to the conference call should dial into (888) 390-3967 (U.S. and International) and ask to be joined to the Amyris, Inc. call. A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: View Source

If you are unable to listen to the live call, the webcast will be archived on the company’s website. A replay of the webcast will be available on the Investor Relations section of the company’s website approximately two hours after the conclusion of the call.

Ribon Therapeutics to Present at Upcoming Healthcare Conferences

On May 4, 2020 Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, reported that Victoria Richon, Ph.D., President and CEO, will present at two upcoming virtual healthcare conferences (Press release, Ribon Therapeutics, MAY 4, 2020, View Source [SID1234556948]). Presentations will consist of a panel discussion and a corporate overview.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

31st Annual Cancer Progress Conference – May 5-6, 2020
Panel: Paradigm-shifting Platforms II, Non-IO: Targeting Better, Targeting the Intractable
Date: May 5, 2020
Time: 11:45 a.m. EDT

Bank of America Securities 2020 HealthCare Conference – May 12-14, 2020
Corporate Presentation
Date: May 12, 2020
Time: 5:00 p.m. EDT

Kitov Pharma Company Presentation – May 2020

On May 4, 2020 Kitov Pharmaceuticals presented the Corporate Presentation (Presentation, Kitov Pharmaceuticals , MAY 4, 2020, View Source [SID1234556964]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Protagonist Therapeutics to Announce First Quarter 2020 Financial Results and Provide Corporate and R&D Update

On May 4, 2020 Protagonist Therapeutics, Inc. (Nasdaq:PTGX) reported that it will announce first quarter financial results after the NASDAQ market closes on Thursday, May 7, 2020 (Press release, Protagonist, MAY 4, 2020, View Source [SID1234556980]). Protagonist management will host a conference call to provide a corporate and R&D update at 5:00 p.m. EDT/2:00 p.m. PDT the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Information

Protagonist executives will host a conference call at 5:00 p.m. EDT/2:00 p.m. PDT on Thursday, May 7, 2020. To access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and refer to conference ID number 4597494. A live and archived webcast of the call will also be accessible in the Investors section of the Company’s website at www.protagonist-inc.com. A replay will be available on the company’s website approximately two hours after the call and will remain available for 60 days.

Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114; Company to Request Additional Meeting with U.S. Food and Drug Administration (“FDA”)

On May 4, 2020 Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) reported an update on its pilot clinical study to assess the unique characteristics of its fulvestrant product candidate, EA-114, which has the potential to enhance estrogen receptor ("ER") inhibition and improve patient outcomes (Press release, Eagle Pharmaceuticals, MAY 4, 2020, View Source [SID1234556949]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As discussed on our March 2nd earnings call, we have continued to refine our EA-114 program, collected additional pilot data, and are pleased with our progress. We have had two meetings with FDA and will request another meeting to discuss these data. With FDA’s guidance, we hope to move ahead with our plans. We look forward to providing additional updates on the progress of this potential drug treatment for hormone-receptor ("HR")-positive advanced breast cancer," stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

"A substantial number of women with advanced HR-positive breast cancer receiving standard treatment experience early disease progression," said Adrian Hepner, Chief Medical Officer of Eagle Pharmaceuticals. "Low and inconsistent estrogen receptor inhibition often results in suboptimal treatment, which may lead to faster progression of the disease. Our research suggests that we may have a better approach."

About Fulvestrant

Fulvestrant, an estrogen receptor antagonist with no agonist properties, is approved by the FDA for the treatment of advanced hormone-related breast cancers. The therapeutic effect of fulvestrant involves its ability to competitively inhibit estrogen-stimulated cell division by binding to the ERs in cancer cells, which may reduce cancer cell proliferation.

Fulvestrant is indicated as a monotherapy treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy, or as a combination therapy for the treatment of: (1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women, in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy, or (2) HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with palbociclib or abemaciclib, in women with disease progression after endocrine therapy.

About Breast Cancer

Breast cancer is the most commonly diagnosed cancer in women, with approximately 290,000 women diagnosed in the U.S. annually and more than 2.8 million breast cancer survivors in the U.S. today. HR-positive breast cancer is the most common clinical subtype, with the ER being expressed in approximately 75% of those diagnosed.